Build status - In Progress

Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)

Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
Recruiting
18 years - 99 years
All
Phase 2
189 participants needed
1 Location

Brief description of study

The main purpose of this study is to measure when the effectiveness of durvalumab in combination with other experimental drugs is superior to the effectiveness of durvalumab when used alone. The study is also being done to evaluate the safety and tolerability of durvalumab when used alone and in combination with other experimental drugs in people with non-small cell lung cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-small Cell Lung Cancer,Lung Cancer,ancer
  • Age: 18 years - 99 years
  • Gender: All

Male or Female Age 18 years or older Documented NSCLC

Updated on 04 Aug 2024. Study ID: 832736

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center